Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)

NCT07015190 is registered in ClinicalTrials.gov with IDEAYA Biosciences as lead sponsor.

NCT NCT07015190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07015190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)
Lead sponsor
IDEAYA Biosciences
Phase
Phase 3
Overall status
Recruiting
Start date
January 25, 2026
Completion date
March 31, 2031
Enrollment
520 (estimated)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

uveal melanoma